Old Web
English
Sign In
Acemap
>
authorDetail
>
Liz Zhong
Liz Zhong
Medicine
Pathology
PI3K/AKT/mTOR pathway
Pharmacodynamics
Pharmacology
2
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.
2017
Journal of Clinical Oncology
Daniel Shao-Weng Tan
Kiat Hon Lim
Wai Meng Tai
Aziah Ahmad
Summer Pan
Quan Sing Ng
Mei-Kim Ang
Apoorva Gogna
Yuen Li Ng
Bien Soo Tan
Haur Yueh Lee
Sakktee Sai Krisna
Dawn Px Lau
Liz Zhong
Gopal Iyer
Balram Chowbay
Alvin St Lim
Angela Takano
Wan-Teck Lim
Eng-Huat Tan
Show All
Source
Cite
Save
Citations (19)
A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers.
2012
Journal of Clinical Oncology
Daniel Shao-Weng Tan
Quan Sing Ng
Dawn Qingqing Chong
Guek Eng Lee
Thuan-Tong Tan
Noan Minh Chau
Mei-Kim Ang
Liz Zhong
Balram Chowbay
John E. Connolly
Eng-Huat Tan
Wan-Teck Lim
Show All
Source
Cite
Save
Citations (0)
1
map